REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Historical Holders from Q1 2014 to Q3 2025

Symbol
REGN on Nasdaq
CUSIP
75886F107
Type / Class
Equity / COMMON STOCK
Shares outstanding
105M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
86.9M
Holdings value
$48.9B
% of all portfolios
0.032%
Grand Portfolio weight change
-0.002%
Number of holders
1217
Number of buys
632
Number of sells
-521
Average Value change %
+0%
Average buys %
+0.009%
Average sells %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JPMORGAN CHASE & CO 4.4% -14% $2.73B -$463M 4.74M -14.5% JPMORGAN CHASE & CO. May 30, 2025
FMR LLC 3.2% -55% $1.88B -$2.7B 3.36M -59% FMR LLC Jun 30, 2025

Institutional Holders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 86.9M $48.9B -$1.22B $562.27 1,217
2025 Q2 89.2M $46.8B -$1.42B $525.00 1,191
2025 Q1 92M $58.3B -$1.19B $634.23 1,271
2024 Q4 93M $66.3B +$318M $712.33 1,287
2024 Q3 91.4M $95.8B -$2.79B $1,051.24 1,365
2024 Q2 93.9M $98.7B +$2.5B $1,051.03 1,315
2024 Q1 91.5M $87.9B +$1.33B $962.49 1,284
2023 Q4 91.3M $80.2B +$1.21B $878.29 1,244
2023 Q3 89.9M $74B -$1.31B $822.96 1,157
2023 Q2 91.8M $66B -$554M $718.54 1,145
2023 Q1 92.4M $75.9B +$73.1M $821.67 1,170
2022 Q4 92.5M $66.7B -$270M $721.49 1,138
2022 Q3 92.7M $63.9B -$196M $688.87 1,060
2022 Q2 93M $55B +$641M $591.13 1,045
2022 Q1 92.2M $64.4B +$1.54B $698.42 1,077
2021 Q4 90M $56.8B +$57.5M $631.52 1,060
2021 Q3 89.9M $54.4B +$778M $605.18 1,002
2021 Q2 88.8M $49.5B -$360M $558.54 953
2021 Q1 89.4M $42.2B -$377M $473.14 900
2020 Q4 90.3M $43.6B -$892M $483.11 887
2020 Q3 91.9M $51.5B -$512M $559.78 897
2020 Q2 92.5M $57.7B +$10.9B $623.65 923
2020 Q1 75M $36.6B +$962M $488.29 805
2019 Q4 73.7M $27.7B +$215M $375.48 684
2019 Q3 73.5M $20.4B -$57.4M $277.40 612
2019 Q2 73.7M $23B -$86M $313.00 649
2019 Q1 73.9M $30.3B +$407M $410.62 704
2018 Q4 73.2M $27.3B -$158M $373.50 660
2018 Q3 73.6M $29.7B +$468M $404.04 636
2018 Q2 72.5M $25B +$77.6M $344.99 614
2018 Q1 72.3M $24.9B +$217M $344.36 613
2017 Q4 71.4M $26.8B -$490M $375.96 630
2017 Q3 72.3M $32.3B -$332M $447.12 602
2017 Q2 73M $35.8B +$1.27B $491.14 597
2017 Q1 71.9M $27.9B +$2.36B $387.51 573
2016 Q4 71.8M $26.3B -$642M $367.09 575
2016 Q3 73.5M $29.5B +$474M $402.02 546
2016 Q2 72.5M $25.3B -$80.5M $349.23 533
2016 Q1 72.6M $26.2B -$262M $360.44 539
2015 Q4 73.2M $39.7B -$79.3M $542.87 572
2015 Q3 73.3M $34.1B -$199M $465.14 559
2015 Q2 73.8M $37.6B +$408M $510.13 532
2015 Q1 73M $32.9B +$441M $451.48 505
2014 Q4 72M $29.6B +$161M $410.25 505
2014 Q3 71.6M $25.8B -$604M $360.52 472
2014 Q2 73.4M $20.7B -$36.1M $282.47 448
2014 Q1 73.4M $22B -$739M $300.28 448